copanlisib (Aliqopa)
Jump to navigation
Jump to search
Indications
- relapsed follicular lymphoma with >= 2 prior systemic therapies
Contraindications
Dosage
- 60 mg IV infusion over 1 hour on days 1, 8, & 15 of a 28-day treatment cycle
- continue until disease progression or unacceptable toxicity
60 mg lyophilized in single-dose vial for reconstitution
Pharmacokinetics
- metabolized by CYP3A
Adverse effects
- hyperglycemia
- hypertension
- pneumonitis
- neutropenia
- skin reactions
- may induce fetal abnormalities
Drug interactions
- avoid concurrent use of strong CYP3A inducers
- reduce dose to 45 mg with concurrent use of strong CYP3A inhibitors
Mechanism of action
More general terms
References
- ↑ Gever J, MedPage Today. September 14, 2017 Novel Kinase Inhibitor OK'd for Follicular Lymphoma. Copanlisib (Aliqopa) approved as third-line therapy. https://www.medpagetoday.com/HematologyOncology/Lymphoma/67913
Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm - ↑ Dreyling M et al. Copanlisib in patients with relapsed or refractory indolent B-cell lymphoma: primary results of the pivotal CHRONOS-1 study. Hematology Oncology. June 7, 2017.
- ↑ Dreyling M, Morschhauser F, Bouabdallah K et al Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017 Sep 1;28(9):2169-2178. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28633365
- ↑ Dreyling M, Santoro A, Mollica L et al Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2017 Dec 10;35(35):3898-3905. Epub 2017 Oct 4. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28976790
- ↑ ALIQOPA. HIGHLIGHTS OF PRESCRIBING INFORMATION https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf